Announcements

Job offersmore »

Tweeting Growers

Top 5 - yesterday

Top 5 - last week

Top 5 - last month

Exchange ratesmore »




Oxford University launches MMJ research programme

Oxford University and Kingsley Capital Partners have launched a new research programme to investigate the role of cannabinoids in biology and medicine.

The programme aims to develop new therapies for acute and chronic conditions including pain, cancer and inflammatory disease.

Through an initial investment of up to £10 million provided by Kingsley, funded through its new portfolio company Oxford Cannabinoid Technologies (OCT), and a series of research projects performed by medical research teams, Oxford will seek to identify new medical therapies through research into the molecular, cellular and systems mechanisms of cannabinoids.

Ahmed Ahmed, Professor of Gynaecological Oncology at Oxford, said: ‘Cannabinoid research has started to produce exciting biological discoveries and this research programme is a timely opportunity to increase our understanding of role of cannabinoids in health and disease. This field holds great promise for developing novel therapeutic opportunities for cancer patients.’

Associate Professor in Clinical Neurosciences, Zameel Cader said: ‘Endocannabinoid signalling is increasingly recognised as fundamentally important in the development and function of the nervous system. This exciting programme of work has the potential to lead to the development of novel therapies for neurological disorders.’

Oxford and Kingsley will host an International Cannabinoid Biomedicine Conference, designed to increase dialogue in the cannabinoid research space, the first of which will take place in Q4 2017.

Neil Mahapatra, Managing Partner of Kingsley, said: ‘Medical cannabis and cannabinoid medicine is already helping patients with some of the most distressing conditions across the world. However, research into the specific pathways and mechanisms that create this benefit is limited and long overdue. Through OCT, we hope our strategic partnership with Oxford will support the development of innovative new therapies to help millions of people around the world. The partnership gives the UK a global leadership role in this fast-growing field.’

The research programme will develop the results into innovative therapies designed to help improve the quality of life of millions of patients. Over time, OCT will fund additional cannabinoid research programmes with the University across different therapeutic areas. This strategic partnership aims to turn Oxford and OCT into a global centre of excellence in cannabinoid research.

For more information:
www.ox.ac.uk

Publication date: 3/16/2017

 


 

Other news in this sector:

8/22/2017 CAN(QC): Havecon to build 250,000 sq. ft. greenhouse for Hydropothecary
8/22/2017 US: 10 states most likely to pass recreational marijuana next
8/22/2017 Video: This is what you call 'protected cropping'
8/22/2017 US (CO): Special forces veteran sues police for MJ greenhouse raid
8/22/2017 US (OH): GreenGro sells 25,000 sq. ft. vertical farm to MMJ grower
8/18/2017 "NFL warms up to marijuana"
8/18/2017 Canada (ON): Enniskillen Pepper Co. makes transition towards marijuana
8/18/2017 CAN (ON): Aphria invests $11.5 million in Scientus Pharma
8/18/2017 US (WA): Oroville MMJ farm approaches first harvest
8/17/2017 Video: James West of Midas letters visits Aphria
8/16/2017 Arkansas: Strict rules prevent companies from applying for cultivator permits
8/16/2017 US (NY): New MMJ licensee to be acquired by investment firm
8/15/2017 Australian government provides update on export of MMJ products
8/15/2017 Canadian company ships first MMJ to Brazil
8/15/2017 US: Maryland regulators approve eight new MMJ growers
8/14/2017 CAN (ON): Aphria teams up with Nuuvera on MMJ greenhouse
8/14/2017 US (OH): Approval for Toledo MMJ operation
8/11/2017 US (NJ): State gives OK to grow medical marijuana in Secaucus
8/11/2017 "Maryland is mired in a medical-marijuana morass"
8/10/2017 US (CA): MedMen featured in CNBC documentary